Pfizer’s sickle cell disease candidate, inclacumab, failed to meet primary endpoints in a pivotal Phase 3 clinical trial, signaling a setback for the company's portfolio in hematology. This follows Pfizer’s prior voluntary market withdrawal of Oxbryta due to safety concerns. The failure highlights ongoing challenges in developing effective therapies for sickle cell disease and may impact investor confidence and Pfizer's R&D direction in this therapeutic area.